Future oncology最新文献

IDeate-Lung02: a Phase 3 study of second-line ifinatamab deruxtecan in patients with relapsed small cell lung cancer. IDeate-Lung02：二线依非那他单抗德鲁西替康治疗复发性小细胞肺癌的3期研究

IF 2.6 4区医学

Future oncology Pub Date : 2025-10-07 DOI: 10.1080/14796694.2025.2565995

Taofeek K Owonikoko, Lauren Byers, Ying Cheng, Hidetoshi Hayashi, Luis Paz-Ares, Maurice Pérol, Haichuan Hu, Meng Qian, Cecilio Roi Garcia, Juliette Godard, Mei Tang, Charles M Rudin

{"title":"IDeate-Lung02: a Phase 3 study of second-line ifinatamab deruxtecan in patients with relapsed small cell lung cancer.","authors":"Taofeek K Owonikoko, Lauren Byers, Ying Cheng, Hidetoshi Hayashi, Luis Paz-Ares, Maurice Pérol, Haichuan Hu, Meng Qian, Cecilio Roi Garcia, Juliette Godard, Mei Tang, Charles M Rudin","doi":"10.1080/14796694.2025.2565995","DOIUrl":"https://doi.org/10.1080/14796694.2025.2565995","url":null,"abstract":"Patients with small cell lung cancer (SCLC) have poor prognosis and limited treatment options beyond first-line therapy. B7 homolog 3 (B7-H3) is minimally expressed in normal tissues but highly expressed in SCLC. Ifinatamab deruxtecan (I-DXd), a B7-H3-directed antibody-drug conjugate, has demonstrated promising efficacy and a manageable safety profile in various tumours, including SCLC. IDeate-Lung02 is a global, randomized, open-label Phase 3 study of ~540 patients with relapsed SCLC. Adults with one prior line of platinum-based systemic therapy, ECOG performance status 0-1, and ≥1 measurable lesion (per RECIST 1.1) are eligible for study participation. Patients with asymptomatic untreated or previously treated brain metastases may participate. Patients are randomized 1:1 to receive I-DXd 12 mg/kg intravenously every 3 weeks or treatment of physician's choice (topotecan, amrubicin, or lurbinectedin). Dual primary endpoints are objective response rate (ORR) by blinded independent central review (BICR) and overall survival. Secondary endpoints include ORR by investigator; progression-free survival, duration of response, disease control rate, and time to response, all by BICR and investigator; patient-reported outcomes; and safety. IDeate-Lung02 will ascertain whether I-DXd treatment after only one prior line of systemic treatment improves outcomes for patients with relapsed SCLC compared with topotecan, amrubicin, or lurbinectedin.Clinical Trial Registration: NCT06203210.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-8"},"PeriodicalIF":2.6,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145238491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognostic implications of cancer-associated fibroblasts and desmoplastic reaction in stage III colon cancer risk groups. 癌症相关成纤维细胞和结缔组织增生反应在III期结肠癌危险人群中的预后意义

IF 2.6 4区医学

Future oncology Pub Date : 2025-10-05 DOI: 10.1080/14796694.2025.2567845

Nazım Can Demircan, Mehmet Fatih Tekin, Tuğba Akın Telli, Rukiye Arıkan, Tuğba Başoğlu, Abdussamet Çelebi, Alper Yaşar, Selver Işık, Özlem Ercelep, Faysal Dane, Çiğdem Ataizi Çelikel, Perran Fulden Yumuk

{"title":"Prognostic implications of cancer-associated fibroblasts and desmoplastic reaction in stage III colon cancer risk groups.","authors":"Nazım Can Demircan, Mehmet Fatih Tekin, Tuğba Akın Telli, Rukiye Arıkan, Tuğba Başoğlu, Abdussamet Çelebi, Alper Yaşar, Selver Işık, Özlem Ercelep, Faysal Dane, Çiğdem Ataizi Çelikel, Perran Fulden Yumuk","doi":"10.1080/14796694.2025.2567845","DOIUrl":"https://doi.org/10.1080/14796694.2025.2567845","url":null,"abstract":"Aim: Risk stratification is used to tailor adjuvant treatment in stage III colon cancer. Cancer associated fibroblasts (CAFs) and desmoplastic reaction (DR) contribute to tumor microenvironment and are associated with tumor progression. We aimed to assess the prognostic value of CAF markers and DR pattern in stage III colon cancer risk groups.Materials and methods: Patients with curative surgery for stage III colon cancer were categorized as low-risk (pT1-3 and pN1) and high-risk (pT4 or pN2). Expressions of fibroblast activation protein α (FAPα), fibroblast specific protein-1 (S100A4) and α-smooth muscle actin (α-SMA) were evaluated semiquantitatively with H-scores. DR pattern was classified as immature, intermediate and mature. Cox regression models were used to determine hazard ratios (HRs) of prognostic factors.Results: Within the study cohort (n = 172), 98 patients had high-risk and 74 had low-risk disease. In the low-risk group, high FAPα expression independently predicted DFS (HR = 3.06, p = 0.02). In the high-risk group, immature DR was an independent prognostic factor for both DFS (HR = 1.99, p = 0.02) and OS (HR = 2.04, p = 0.02).Conclusion: FAPα as a surrogate marker of CAFs and DR pattern may have distinct prognostic impacts in stage III colon cancer risk groups and be utilized to refine prognosis further in these patients.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-10"},"PeriodicalIF":2.6,"publicationDate":"2025-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145232443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

EA1211: interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy (DIRECT trial). EA1211：预测her2阳性乳腺癌对新辅助治疗反应的中期FDG-PET/CT（直接试验）。

IF 2.6 4区医学

Future oncology Pub Date : 2025-10-05 DOI: 10.1080/14796694.2025.2567840

Maeve A Hennessy, Constantine Gatsonis, Heather Jacene, Roisin M Connolly, Brian L Burnette, Erica M Stringer-Reasor, Justin Romanoff, Alexander Taurone, Ciara C O'Sullivan, Huong T Le-Petross, Vered Stearns, Amy M Fowler, Shou-Ching Tang, Karla A Sepulveda, Angela M DeMichele, David A Mankoff, Antonio C Wolff

引用次数: 0

Oncologists' preferences for frontline TKI treatment of Ph+ acute lymphoblastic leukemia: a discrete choice experiment. 肿瘤学家对一线TKI治疗Ph+急性淋巴细胞白血病的偏好：离散选择实验。

IF 2.6 4区医学

Future oncology Pub Date : 2025-10-05 DOI: 10.1080/14796694.2025.2565497

Ajibade Ashaye, Natasha Ramachandran, Matthew Quaife, Yanyu Wu, Álvaro Alberto Gutiérrez-Vargas, Angelica Jiongco, Vamsi Kota, Bipin Savani, Caitlin Thomas

{"title":"Oncologists' preferences for frontline TKI treatment of Ph+ acute lymphoblastic leukemia: a discrete choice experiment.","authors":"Ajibade Ashaye, Natasha Ramachandran, Matthew Quaife, Yanyu Wu, Álvaro Alberto Gutiérrez-Vargas, Angelica Jiongco, Vamsi Kota, Bipin Savani, Caitlin Thomas","doi":"10.1080/14796694.2025.2565497","DOIUrl":"https://doi.org/10.1080/14796694.2025.2565497","url":null,"abstract":"Aims: To evaluate hematologist-oncologists' preferences for frontline treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) using tyrosine kinase inhibitors (TKIs) + chemotherapy.Participants & methods: An online discrete choice experiment was conducted among US-based hematologist-oncologists. Participants viewed profiles of hypothetical TKI + chemotherapy treatments with varied levels of benefit and risks (minimal residual disease-negative complete remission [MRD-negative CR], arterial occlusive events, grade 3-4 hepatotoxicity, grade 3-4 hematotoxicity) and chose their recommended treatment for five patient profiles: \"less-complex\" baseline; age ≥ 65; ECOG score 3; diabetes; hypertension. Data were analyzed using mixed multinomial logit models.Results: 121 hematologist-oncologists participated. Increasing MRD-negative CR was most important to hematologist-oncologists, driving 65%-87% of decision-making across patient profiles. Relative importance of benefits/risks varied by patient profile. Pooled across patient profiles, hepatotoxicity was the most concerning risk, driving 14% of decision-making. Based on PhALLCON data and elicited preferences, hematologist-oncologists were predicted to select the profile of ponatinib + chemotherapy over imatinib + chemotherapy for all included patient profiles. Predicted probabilities of choosing ponatinib over imatinib ranged from 87%-98% across patient profiles.Conclusions: Hematologist-oncologists prioritized achieving MRD-negative CR when recommending frontline treatments for Ph+ ALL, accepting some risks if offset by meaningful improvement in MRD-negative CR.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-14"},"PeriodicalIF":2.6,"publicationDate":"2025-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145232377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Does neoadjuvant chemoimmune therapy confer benefits to all NSCLC patients? 新辅助化疗免疫治疗对所有NSCLC患者都有益处吗？

IF 2.6 4区医学

Future oncology Pub Date : 2025-10-03 DOI: 10.1080/14796694.2025.2565828

Miao Huang, Bing Liu, Xinrun Cui, Ye Tao, Nan Wu

引用次数: 0

Pirtobrutinib in the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma. 吡托鲁替尼治疗慢性淋巴细胞白血病或小淋巴细胞淋巴瘤。

IF 2.6 4区医学

Future oncology Pub Date : 2025-10-03 DOI: 10.1080/14796694.2025.2567834

Syed Ibrahim, Nghia Pham, Aarushi Sahni, Samantha Sekeres, Allison Cool, Justin Taylor, Catherine C Coombs

引用次数: 0

Treatment options in hormone-sensitive prostate cancer: targeting the androgen-sensitive pathway. 激素敏感前列腺癌的治疗选择：针对雄激素敏感途径。

IF 2.6 4区医学

Future oncology Pub Date : 2025-10-03 DOI: 10.1080/14796694.2025.2561320

Cora N Sternberg, Alicia K Morgans

引用次数: 0

Real-world characteristics, treatment patterns, and outcomes of patients with mantle cell lymphoma by line of therapy. 套细胞淋巴瘤患者的现实世界特征、治疗模式和治疗结果。

IF 2.6 4区医学

Future oncology Pub Date : 2025-10-03 DOI: 10.1080/14796694.2025.2565829

Helmneh M Sineshaw, Claire Bai, Enrico de Nigris, Jennifer Prescott, Uzor Ogbu, Christina M Zettler, Laura L Fernandes, Ching-Kun Wang

{"title":"Real-world characteristics, treatment patterns, and outcomes of patients with mantle cell lymphoma by line of therapy.","authors":"Helmneh M Sineshaw, Claire Bai, Enrico de Nigris, Jennifer Prescott, Uzor Ogbu, Christina M Zettler, Laura L Fernandes, Ching-Kun Wang","doi":"10.1080/14796694.2025.2565829","DOIUrl":"https://doi.org/10.1080/14796694.2025.2565829","url":null,"abstract":"Background: Approvals of Bruton's tyrosine kinase inhibitors (BTKis) and other novel agents have changed the Mantle Cell Lymphoma (MCL) treatment paradigm, necessitating assessment of contemporaneous, real-world (rw) treatment and outcomes by line of therapy (LOT).Methods: Patients diagnosed with MCL on or after 1 January 2012 who initiated first-line (1 L) treatment in the COTA database were eligible, excluding those with concurrent primaries, history of hematologic malignancies, clinical trial participation, or missing/imprecise key dates. Rw time to next treatment (rwTTNT) and overall survival (rwOS) were evaluated using the Kaplan-Meier method from LOT start (index).Results: Of 499 patients, most were ≥ 50 years (94.8%), male (71.5%), treated in the community (58.7%), and diagnosed with stage III/IV disease (91.2%). The most common 1 L regimen was bendamustine+rituximab (BR)±R maintenance (12.6%/23.0%, respectively). Fifty (10.0%) patients received 1 L autologous stem cell transplant. One hundred and seventy-three patients (34.7%) received 2 L, of which 72 (41.6% of 2 L) received 3 L, of which 29 (40.3% of 3 L) received 4 L +. BTKi monotherapy was the most frequently administered therapy in 2 L (26.0%).Median rwTTNT and rwOS from 1 L to 4 L were 36.8-3.2 and 86.2-8.7 months, respectively.Conclusions: Outcomes of patients who received 2 L+ for MCL remain poor, highlighting unmet need in the contemporary treatment paradigm.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-11"},"PeriodicalIF":2.6,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145212506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Finding the right tool for the specific task: navigating RWE tools and checklists. 为特定任务找到正确的工具：导航RWE工具和检查表。

IF 2.6 4区医学

Future oncology Pub Date : 2025-10-01 Epub Date: 2025-09-01 DOI: 10.1080/14796694.2025.2552098

Richard Willke, Paul Cottu, Andrew Briggs, Uwe Siebert, Connie Chen, Beata Korytowsky, Julien Heidt, Meghan Renfrow, Kate Lovett, Adam Brufsky

{"title":"Finding the right tool for the specific task: navigating RWE tools and checklists.","authors":"Richard Willke, Paul Cottu, Andrew Briggs, Uwe Siebert, Connie Chen, Beata Korytowsky, Julien Heidt, Meghan Renfrow, Kate Lovett, Adam Brufsky","doi":"10.1080/14796694.2025.2552098","DOIUrl":"10.1080/14796694.2025.2552098","url":null,"abstract":"Real-world evidence (RWE) is increasingly used to support product approvals and label expansions, as well as clinical and payer decision-making. Various tools (e.g. frameworks, checklists) have been developed to help inform and assess the robustness and quality of real-world study design and reporting. This targeted review provides a practical guide for leveraging these tools to increase awareness and utility for decision-makers. A pre-defined search strategy was applied to identify articles from PubMed. Articles published from 1 January 2020, through 4 October 2024 were included and reviewed to identify relevant tools aimed at assessing RWE study planning, reporting, or quality assessment. Key information regarding each was extracted and summarized including strengths, limitations, and included domains. 119 articles were initially identified, of which 15 were included after screening, referencing a total of 17 tools. These 17 tools varied in format and structure, ranging from detailed guidelines and templates to checklists and questionnaires. Utility and application of the tools identified in this targeted review vary across the evaluation of study planning, reporting, and quality. Selection of the appropriate tool depends on several factors including intended purpose of the tool, intended real-world study design, and the availability of study documentation.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"3075-3089"},"PeriodicalIF":2.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12490408/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144951057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Long-term safety and effectiveness of ruxolitinib in patients with myelofibrosis in Japan: an observational study. 鲁索利替尼在日本骨髓纤维化患者中的长期安全性和有效性：一项观察性研究。

IF 2.6 4区医学

Future oncology Pub Date : 2025-10-01 Epub Date: 2025-08-29 DOI: 10.1080/14796694.2025.2550924

Yusuke Aruga, Wataru Hongo, Weizhe Lu

{"title":"Long-term safety and effectiveness of ruxolitinib in patients with myelofibrosis in Japan: an observational study.","authors":"Yusuke Aruga, Wataru Hongo, Weizhe Lu","doi":"10.1080/14796694.2025.2550924","DOIUrl":"10.1080/14796694.2025.2550924","url":null,"abstract":"Aim: To evaluate the safety and effectiveness of ruxolitinib in patients with myelofibrosis (MF) in Japan.Methods: A multicenter, observational study of patients who received ruxolitinib for MF from July 2014.Results: Of 892 patients (mean age: 70 years, 45.9% primary MF, ruxolitinib treatment median duration, 541.0 days), 67.7% had adverse drug reactions (ADRs) and 31.5% had serious ADRs. The most frequent ADRs were anemia and decreased platelet count. Incidences of ADRs by time of onset were 57.7%, 20.3%, 14.4%, 11.1%, 11.3%, 9.0%, and 1.8% from the treatment initiation to Day 182, and every 6 months thereafter until Day 1,093 or later, respectively. ADRs of special interest included myelosuppression (46.8%), infections (17.6%), hepatic impairment (13.5%), hemorrhagic events (10.2%), cardiac failure (2.5%), interstitial lung disease (1.5%), malignancy (1.4%) and tuberculosis (0.5%). Incidences of common ADRs were similar between patients with hepatic or renal impairment and patients without hepatic or renal impairment. At 6 months, spleen responses and symptom improvement were observed in 26.2% and 52.0% of patients, respectively. Median overall survival was not reached.Conclusion: In a real-world setting in Japan, ruxolitinib demonstrated a reasonable degree of effectiveness with no new safety concerns. Results were similar to those from clinical trials.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"3017-3026"},"PeriodicalIF":2.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12490404/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144951138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0